Filtern
Volltext vorhanden
- ja (4)
Gehört zur Bibliographie
- ja (4)
Dokumenttyp
Sprache
- Englisch (4)
Schlagworte
- Parkinson's disease (2)
- skin biopsy (2)
- Biomarker (1)
- Biopsie (1)
- Haut (1)
- MIBG scintigraphy (1)
- Parkinson-Krankheit (1)
- T cells (1)
- alpha-synuclein (1)
- biomarker (1)
- cancer microenvironment (1)
- diagnostic markers (1)
- immunotherapy (1)
- multiple system atrophy (1)
- parkinson's disease (1)
- peripheral nervous system (1)
- tumour immunology (1)
Institut
- Neurologische Klinik und Poliklinik (3)
- Frauenklinik und Poliklinik (1)
- Institut für Virologie und Immunbiologie (1)
- Kinderklinik und Poliklinik (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Klinik und Poliklinik für Nuklearmedizin (1)
- Medizinische Klinik und Poliklinik II (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.